<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3007233939
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Nurtec
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIMEGEPANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet, orally disintegrating
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        607.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT UK SWINDON ZYDIS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT UK SWINDON ZYDIS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NURTEC contains the active ingredient rimegepant, that stops the activity of a substance in the body called calcitonin gene-related peptide (CGRP). People with migraine may have increased levels of CGRP.</p><p>Rimegepant attaches to the receptor for CGRP, reducing the ability of CGRP to also attach to the receptor. This reduces the activity of CGRP and has two effects:</p><p>1) it can stop an active migraine attack, and</p><p>2) it can decrease the number of migraine attacks that occur when taken preventively.</p><p>&nbsp;</p><p>NURTEC is used to treat and prevent migraine attacks in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take NURTEC</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rimegepant or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking NURTEC, if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have reduced kidney function or are on kidney dialysis</p><p>&nbsp;</p><p>During treatment with NURTEC, stop taking this medicine and tell your doctor immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience any symptoms of an allergic reaction, e.g., trouble breathing or severe rash. These symptoms can occur several days after administration.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>NURTEC should not be given to children and adolescents under 18&nbsp;years of age because it has not yet been studied in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and NURTEC</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines may affect the way NURTEC works or NURTEC may affect how other medicines work.</p><p>&nbsp;</p><p>The following is a list of examples of medicines that should be avoided when taking NURTEC:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole and clarithromycin (medicines used to treat fungal or bacterial infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir and efavirenz (medicines to treat HIV infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (a medicine used to treat high blood pressure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (a herbal remedy used to treat depression).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital (a medicine used to treat epilepsy).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a medicine used to treat tuberculosis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil (a medicine used to treat narcolepsy).</p><p>&nbsp;</p><p>Do not take NURTEC more than once every 48&nbsp;hours with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluconazole and erythromycin (medicines used to treat fungal or bacterial infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem, quinidine, and verapamil (medicines used to treat an abnormal heart rhythm, chest pain (angina) or high blood pressure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporin (a medicine used to prevent organ rejection after an organ transplant).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is preferable to avoid the use of NURTEC during pregnancy as the effects of this medicine in pregnant women are not known.</p><p>&nbsp;</p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor or pharmacist before using this medicine. You and your doctor should decide if you will use NURTEC while breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>NURTEC is not expected to affect your ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take NURTEC</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rimegepant or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking NURTEC, if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have reduced kidney function or are on kidney dialysis</p><p>&nbsp;</p><p>During treatment with NURTEC, stop taking this medicine and tell your doctor immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience any symptoms of an allergic reaction, e.g., trouble breathing or severe rash. These symptoms can occur several days after administration.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>NURTEC should not be given to children and adolescents under 18&nbsp;years of age because it has not yet been studied in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and NURTEC</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines may affect the way NURTEC works or NURTEC may affect how other medicines work.</p><p>&nbsp;</p><p>The following is a list of examples of medicines that should be avoided when taking NURTEC:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole and clarithromycin (medicines used to treat fungal or bacterial infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir and efavirenz (medicines to treat HIV infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (a medicine used to treat high blood pressure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (a herbal remedy used to treat depression).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital (a medicine used to treat epilepsy).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a medicine used to treat tuberculosis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil (a medicine used to treat narcolepsy).</p><p>&nbsp;</p><p>Do not take NURTEC more than once every 48&nbsp;hours with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluconazole and erythromycin (medicines used to treat fungal or bacterial infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem, quinidine, and verapamil (medicines used to treat an abnormal heart rhythm, chest pain (angina) or high blood pressure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporin (a medicine used to prevent organ rejection after an organ transplant).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is preferable to avoid the use of NURTEC during pregnancy as the effects of this medicine in pregnant women are not known.</p><p>&nbsp;</p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor or pharmacist before using this medicine. You and your doctor should decide if you will use NURTEC while breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>NURTEC is not expected to affect your ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop using NURTEC and contact your doctor straight away if you have signs of an allergic reaction</strong> such as severe rash or shortness of breath. Allergic reactions with NURTEC are uncommon (may affect up to 1 in 100 people).</p><p>&nbsp;</p><p>A common side effect (may affect up to 1 in 10 people) is nausea.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/<strong>&nbsp;&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C. Store in the original blister in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is rimegepant. Each orally disintegrating tablet contains 75&nbsp;mg rimegepant (as sulfate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are gelatin, mannitol, mint flavour, and sucralose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	NURTEC 75 mg orally disintegrating tablet is white to off-white, circular, and debossed with the symbol  .
	
	Pack size
•	8 x 1 orally disintegrating tablet perforated unit dose blisters.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Catalent UK Swindon Zydis Ltd.</p><p>Frankland Road, Blagrove</p><p>Swindon, Wiltshire</p><p>SN5 8RU</p><p>United Kingdom</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نورتك على المكون الفعال ريميجيبانت، الذي يمنع نشاط مادة يفرزها الجسم تسمى الببتيد المرتبط بجين الكالسيتونين (CGRP). قد يكون لدى الأشخاص المصابين بالصداع النصفي مستويات متزايدة من الببتيد المرتبط بجين الكالسيتونين.</p><p dir="RTL">يرتبط ريميجيبانت بمستقبل الببتيد المرتبط بجين الكالسيتونين، مما يقلل من قدرة الببتيد المرتبط بجين الكالسيتونين على الارتباط أيضًا بالمستقبل. وهذا يقلل من نشاط الببتيد المرتبط بجين الكالسيتونين وله تأثيران:</p><p dir="RTL">۱) يمكن أن يوقف نوبة صداع نصفي نشطه</p><p dir="RTL">۲) ويمكن أن يقلل من عدد نوبات الصداع النصفي التي تحدث عند تناوله بشكل وقائي.</p><p>&nbsp;</p><p dir="RTL">يُستخدم نورتك لعلاج نوبات الصداع النصفي ويقي من الإصابة بها لدى البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال نورتك</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه ريميجيبانت أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال نورتك</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول نورتك، إذا انطبق أي مما يلي عليك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور في وظائف الكلى أو كنت تخضع للغسيل الكلوي.</p><p>&nbsp;</p><p dir="RTL">أثناء العلاج بنورتك، توقف عن تناول هذا الدواء وأخبر طبيبك على الفور:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي أعراض لتفاعل حساسية، على سبيل المثال، صعوبة في التنفس أو طفح جلدي شديد. يمكن أن تحدث هذه الأعراض بعد عدة أيام من تناوله.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ينبغي عدم إعطاء نورتك للأطفال والمراهقين الذين تقل أعمارهم عن ۱۸ عامًا لأنه لم تتم دراسة تأثيره بعد على هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى. هذا لأن بعض الأدوية قد تؤثر على طريقة عمل نورتك أو قد يؤثر نورتك على طريقة عمل الأدوية الأخرى.</p><p>&nbsp;</p><p dir="RTL">فيما يلي قائمة بأمثلة على الأدوية التي ينبغي تجنب تناولها عند تناول نورتك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتراكونازول وكلاريثروميسين (دواءان يُستخدمان لعلاج حالات العدوى الفطرية أو البكتيرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير وإيفافيرينز (دواءان يُستخدمان لعلاج حالات عدوى فيروس نقص المناعة البشرية (HIV)).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسنتان (دواء يُستخدم لعلاج ضغط الدم المرتفع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (علاج عشبي يُستخدم لعلاج الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (دواء يُستخدم لعلاج الصرع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (دواء يُستخدم لعلاج السل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مودافينيل (دواء يُستخدم لعلاج النوم القهري).</p><p>&nbsp;</p><p dir="RTL">لا تأخذ نورتك لأكثر من مرة واحدة كل ٤۸ ساعة مع:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول وإريثروميسين (دواءان يُستخدمان لعلاج حالات العدوى الفطرية أو البكتيرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم، وكينيدين، وفيراباميل (أدوية تُستخدم لعلاج اضطراب نظم القلب، أو ألم الصدر (الذبحة الصدرية)، أو ضغط الدم المرتفع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء يُستخدم لمنع رفض الجسم للعضو بعد زرعه).</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء. يُفضل تجنب استخدام نورتك أثناء الحمل لأن تأثيرات هذا الدواء على النساء الحوامل غير معروفة.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ ترضعين رضاعة طبيعية أو تخططين لذلك، فتحدثي مع طبيبكِ أو الصيدلي قبل استخدام هذا الدواء. ينبغي أن تقرري أنتِ وطبيبكِ ما إذا كنتِ سوف تستخدمين نورتك أثناء الرضاعة الطبيعية أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير نورتك على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المتوقع أن يؤثر نورتك على قدرتك على القيادة أو استخدام الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على أخذ هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL"><strong>الكمية التي ينبغي تناولها</strong></p><p dir="RTL">لمنع الإصابة بالصداع النصفي، الجرعة الموصى بها هي قرص واحد ينحل بالفم (٧٥ ملجم ريميجيبانت) كل يومين.</p><p>&nbsp;</p><p dir="RTL">لعلاج نوبة الصداع النصفي بمجرد الإصابة بها، تكون الجرعة الموصى بها قرصًا واحدًا ينحل بالفم (٧٥ ملجم ريميجيبانت) حسب الحاجة، ويجب ألا تزيد الجرعة عن قرص واحد يوميًا.</p><p>&nbsp;</p><p dir="RTL">الحد الأقصى للجرعة اليومية هو قرص واحد ينحل بالفم (٧٥ ملجم ريميجيبانت) في اليوم.</p><p>&nbsp;</p><p dir="RTL"><strong>كيفية تناول هذا الدواء</strong></p><p dir="RTL">يُستخدم نورتك عن طريق الفم.</p><p dir="RTL">يمكن تناول قرص ينحل بالفم مع الطعام أو الماء، أو دونهما.</p><p>&nbsp;</p><p dir="RTL">التعليمات:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_13" o:spid="_x0000_i1026" type="#_x0000_t75"
   alt="A picture containing clipart&#10;&#10;Description automatically generated"
   style='width:61.5pt;height:61.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image001.png"
    o:title="A picture containing clipart&#10;&#10;Description automatically generated"/>
  </v:shape><![endif]--><img width="82" height="82" alt="A picture containing clipart

Description automatically generated" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image002.gif" /></p><p dir="LTR">&nbsp;</p></td><td><p dir="RTL">استخدم يدين جافتين عند فتح العبوة. قم بإزالة الرقاقة المعدنية التي تغطي وحدة واحدة من شريط البليستر وأخرج برفق قرص ينحل بالفم. <strong>لا</strong> تدفع قرص ينحل بالفم لإخراجه من الرقاقة المعدنية.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_14" o:spid="_x0000_i1025"
   type="#_x0000_t75" alt="Diagram&#10;&#10;Description automatically generated with low confidence"
   style='width:61.5pt;height:65pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image003.png"
    o:title="Diagram&#10;&#10;Description automatically generated with low confidence"/>
  </v:shape><![endif]--><img width="82" height="87" alt="Diagram

Description automatically generated with low confidence" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image004.gif" /></p><p dir="LTR">&nbsp;</p></td><td><p dir="RTL">بمجرد فتح وحدة شريط البليستر، أخرج قرص ينحل بالفم وضعه على لسانك أو أسفله حيث سيذوب. لا يلزم شرب أي سائل أو ماء.</p><p dir="RTL">لا تخزن قرص ينحل بالفم خارج شريط البليستر لاستخدامه لاحقًا.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الزائدة من نورتك</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو توجه للمستشفى فورًا. وأحضر عبوة الدواء وهذه النشرة معك.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>نسيان تناول جرعة نورتك</strong></p><p dir="RTL">إذا كنت تتناول نورتك لمنع الإصابة بالصداع النصفي ونسيت تناول جرعة، فما عليك سوى تناول الجرعة التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يُسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>توقف عن تناول نورتك وتواصل مع طبيبك فورًا إذا أُصبت بأي علامات لتفاعل حساسية</strong> مثل طفح جلدي شديد أو ضيق التنفس. تعد الإصابة بتفاعلات الحساسية تجاه نورتك أمرًا غير شائع (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص).</p><p>&nbsp;</p><p dir="RTL">الغثيان هو أثر جانبي شائع (قد يُصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ القومي. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية وشريط البليستر بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يُخزن في درجة حرارة أقل من ۳۰ درجة مئوية. ويُخزن في عبوة شريط البليستر الأصلية لحمايته من الرطوبة.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي ريميجيبانت. يحتوي كل قرص ينحل بالفم على ٧٥ ملجم ريميجيبانت (في صورة كبريتات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كحول بنزيلي، ويوكاليبتول، وجيلاتين، وليمونين، ومانيتول، ومينثول، ومينثون، وأسيتات المينثيل، وسكرالوز، وفانيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تكون قرص نورتك ٧٥ ملجم ينحل بالفم من بيضاء إلى بيضاء مائلة إلى الصفرة، ودائرية الشكل، ومحفور عليها الرمز <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:9pt;height:11pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="12" height="15" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image002.gif" />.</p><p>&nbsp;</p><p dir="RTL">حجم العبوة:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>شريط بليستر واحد به ۸ أقراص تنحل بالفم، قابل للفصل للجرعات الفردية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p>Pfizer Europe MA EEIG</p><p dir="RTL">Belgium، بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">Catalent UK Swindon Zydis Ltd.</p><p dir="RTL">Frankland Road, Blagrove</p><p dir="RTL">Swindon, Wiltshire</p><p dir="RTL">SN5 8RU</p><p dir="RTL">United Kingdom، المملكة المتحدة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو/حزيران ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NURTEC75 mg orally disintegrating tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each orally disintegrating tablet contains rimegepant sulfate, equivalent to 75 mg rimegepant.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orally disintegrating tablet (ODT): 
The orally disintegrating tablet is white to off-white, circular, diameter 14 mm and debossed with the symbol  .

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NURTEC is indicated for the</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Acute treatment of migraine with or without aura in adults;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Acute treatment of migraine</em></p><p>The recommended dose is 75&nbsp;mg rimegepant, as needed, once daily.</p><p>&nbsp;</p><p><em>Prophylaxis of migraine</em></p><p>The recommended dose is 75&nbsp;mg rimegepant every other day.</p><p>&nbsp;</p><p>The maximum dose per day is 75&nbsp;mg rimegepant.</p><p>&nbsp;</p><p>NURTEC can be taken with or without meals.</p><p>&nbsp;</p><p><em>Concomitant medicinal products</em></p><p>Another dose of rimegepant should be avoided within 48&nbsp;hours when it is concomitantly administered with moderate inhibitors of CYP3A4 or with strong inhibitors of P-gp (see section 4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>&nbsp;</u></em></p><p><em>Elderly (aged 65 and over)</em></p><p>There is limited experience with rimegepant in patients aged 65&nbsp;years or older. No dose adjustment is required as the pharmacokinetics of rimegepant are not affected by age (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with mild, moderate, or severe renal impairment. Severe renal impairment resulted in a &gt;&nbsp;2-fold increase in unbound AUC but less than a 50% increase in total AUC (see section&nbsp;5.2). Caution should be exercised during frequent use in patients with severe renal impairment. Rimegepant has not been studied in patients with end-stage renal disease and in patients on dialysis. Use of rimegepant in patients with end-stage renal disease (CLcr&nbsp;&lt;&nbsp;15&nbsp;ml/min) should be avoided.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations (unbound AUC) of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment (see section&nbsp;5.2). The use of rimegepant in patients with severe hepatic impairment should be avoided.</p><p><em><u>&nbsp;</u></em></p><p><em>Pediatric population</em></p><p>The safety and efficacy of NURTEC in pediatric patients (&lt;&nbsp;18 years of age) have not been established. No data are available.</p><p><em>&nbsp;</em></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>NURTEC is for oral use.</p><p><u>&nbsp;</u></p><p>The orally disintegrating tablet should be placed on the tongue or under the tongue. It will disintegrate in the mouth and can be taken without liquid.</p><p>&nbsp;</p><p>Patients should be advised to use dry hands when opening the blister and referred to the package leaflet for complete instructions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions, including dyspnoea and rash, have occurred in less than 1% of patients treated with rimegepant in clinical studies (see section&nbsp;4.8). Hypersensitivity reactions, including serious hypersensitivity, can occur days after administration. If a hypersensitivity reaction occurs, rimegepant should be discontinued and appropriate therapy should be initiated.</p><p>&nbsp;</p><p>NURTEC is not recommended:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with severe hepatic impairment (see section&nbsp;4.2);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with end-stage renal disease (CLcr&nbsp;&lt;&nbsp;15&nbsp;ml/min) (see section&nbsp;4.2);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for concomitant use with strong inhibitors of CYP3A4 (see section&nbsp;4.5);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for concomitant use with strong or moderate inducers of CYP3A4 (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Medication overuse headache (MOH)</p><p>Overuse of any type of medicinal products for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained, and treatment should be discontinued. The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of medicinal products for acute headache.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>rimegepant is a substrate of CYP3A4, P-glycoprotein (P‑gp) and breast cancer resistance protein (BCRP) efflux transporters (see section&nbsp;5.2).</p><p><u>&nbsp;</u></p><p><u>CYP3A4 inhibitors</u></p><p>&nbsp;</p><p>Inhibitors of CYP3A4 increase plasma concentrations of rimegepant. Concomitant administration of rimegepant with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) is not recommended (see section&nbsp;4.4). Concomitant administration of rimegepant with itraconazole resulted in a significant increase in rimegepant exposure (AUC by 4-fold and C<sub>max</sub> 1.5-fold).</p><p>&nbsp;</p><p>Concomitant administration of rimegepant with medicinal products that moderately inhibit CYP3A4 (e.g., diltiazem, erythromycin, fluconazole) may increase exposure to rimegepant. Concomitant administration of rimegepant with fluconazole resulted in increased exposures of rimegepant (AUC by 1.8-fold) with no relevant effect on C<sub>max</sub>. Another dose of rimegepant within 48&nbsp;hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4 (e.g., fluconazole) (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>CYP3A4 inducers</u></p><p>&nbsp;</p><p>Inducers of CYP3A4 decrease plasma concentrations of rimegepant. Concomitant administration of NURTEC with strong CYP3A4 inducers (e.g., phenobarbital, rifampicin, St John&rsquo;s wort (<em>Hypericum perforatum</em>)) or moderate CYP3A4 inducers (e.g., bosentan, efavirenz, modafinil) is not recommended (see section&nbsp;4.4). The effect of CYP3A4 induction may last for up to 2&nbsp;weeks after discontinuation of the strong or moderate CYP3A4 inducer. Concomitant administration of rimegepant with rifampicin resulted in a significant decrease (AUC reduced by 80% and C<sub>max</sub> by 64%) in rimegepant exposure, which may lead to loss of efficacy.</p><p>&nbsp;</p><p><u>P-gp and BCRP only inhibitors</u></p><p>&nbsp;</p><p>Inhibitors of P‑gp and BCRP efflux transporters may increase plasma concentrations of rimegepant. Another dose of NURTEC within 48&nbsp;hours should be avoided when it is concomitantly administered with strong inhibitors of P‑gp (e.g., cyclosporine, verapamil, quinidine) (see section&nbsp;4.2). Concomitant administration of rimegepant with cyclosporine (a potent P‑gp and BCRP inhibitor) or with quinidine (a selective P‑gp inhibitor) resulted in a significant increase of similar magnitude in rimegepant exposure (AUC and C<sub>max</sub> by &gt;&nbsp;50%, but less than two-fold).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are limited data from the use of rimegepant in pregnant women. Animal studies demonstrate that rimegepant is not embryocidal, and no teratogenic potential has been observed at clinically relevant exposures. Adverse effects on embryo-foetal development (decreased foetal body weight and increased skeletal variations in rats) were only observed at exposure levels associated with maternal toxicity (approximately 200&nbsp;times greater than clinical exposures) following administration of rimegepant during pregnancy (see section&nbsp;5.3). As a precautionary measure, it is preferable to avoid the use of NURTEC Oral &nbsp;during pregnancy.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In a single center study of 12 breast-feeding women treated with a single dose of rimegepant 75&nbsp;mg, minimal concentrations of rimegepant were observed in breast milk. The relative percentage of a maternal dose estimated to reach the infant is less than 1%. There are no data on the effects on milk production. The developmental and health benefits of breast-feeding should be considered along with the mother&rsquo;s clinical need for NURTEC and any potential adverse reactions on the breastfed infant from rimegepant or from the underlying maternal condition.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies showed no clinically relevant impact on female and male fertility (see section&nbsp;5.3)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NURTEC has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common adverse reaction was nausea for acute treatment (1.2%) and for migraine prophylaxis (1.4%). Most of the reactions were mild or moderate in severity. Hypersensitivity, including dyspnoea and severe rash, occurred in less than 1% of patients treated.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Adverse reactions are listed by MedDRA system organ class in Table&nbsp;1. The corresponding frequency category for each drug reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction </strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Acute Treatment </strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity, including dyspnoea and severe rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Prophylaxis</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Long-term safety</em></p><p>Long-term safety of rimegepant was assessed in two one year, open-label extensions; 1662 patients received rimegepant for at least 6 months and 740 received rimegepant for 12 months for acute or prophylactic treatment.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Hypersensitivity reactions</em></p><p>Hypersensitivity, including dyspnoea and severe rash, occurred in less than 1% of patients treated in clinical studies. Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Center (NPC).</p><p>To Report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:408px"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Center (NPC)</p><p>o&nbsp;&nbsp; Call center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical experience with rimegepant overdose. No overdose symptoms have been reported. Treatment of an overdose of rimegepant should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. No specific antidote for the treatment of rimegepant overdose is available. Rimegepant is unlikely to be significantly removed by dialysis because of high serum protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Analgesics, calcitonin gene-related peptide (CGRP) antagonists, ATC code: N02CD06</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Rimegepant selectively binds with high affinity to the human calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.</p><p>&nbsp;</p><p>The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy: acute treatment</u></p><p><u>&nbsp;</u></p><p>The efficacy of NURTEC for the acute treatment of migraine with and without aura in adults was studied in three randomized, double-blind, placebo-controlled trials (Studies 1-3). Patients were instructed to treat a migraine of moderate to severe headache pain intensity. Rescue medicinal products (i.e., NSAIDs, paracetamol, and/or an antiemetic) was allowed 2&nbsp;hours after the initial treatment. Other forms of rescue medicinal products such as triptans were not allowed within 48&nbsp;hours of initial treatment. Approximately 14% of patients were taking preventive medicinal products for migraine at baseline. None of the patients in Study&nbsp;1 were on concomitant preventive medicinal products that act on the calcitonin gene-related peptide pathway.</p><p>&nbsp;</p><p>The primary efficacy analyses were conducted in patients who treated a migraine with moderate to severe pain. Pain freedom was defined as a reduction of moderate or severe headache pain to no headache pain, and most bothersome symptom (MBS) freedom was defined as the absence of the self‑identified MBS (i.e., photophobia, phonophobia, or nausea). Among patients who selected an MBS, the most commonly selected symptom was photophobia (54%), followed by nausea (28%), and phonophobia (15%).</p><p>&nbsp;</p><p>In Study&nbsp;1, the percentage of patients achieving headache pain freedom and MBS freedom at 2 hours after a single dose was statistically significantly greater in patients who received NURTEC compared to those who received placebo (Table&nbsp;2). In addition, statistically significant effects of NURTEC compared to placebo were demonstrated for the additional efficacy endpoints of pain relief at 2&nbsp;hours, sustained pain freedom from 2 to 48&nbsp;hours, use of rescue medication within 24&nbsp;hours, and ability to function normally at 2 hours after dosing. Pain relief was defined as a reduction in migraine pain from moderate or severe severity to mild or none. Pivotal single attack, double-blind, placebo-controlled studies 2 &amp; 3 were conducted in patients with migraine who received one 75&nbsp;mg rimegepant bioequivalent dosage form.</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Migraine Efficacy Endpoints for Acute Treatment Studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 3</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>VYDURA</strong><strong> 75&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Rimegepant 75 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Rimegepant 75 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pain Free at 2&nbsp;hours</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n/N*</p></td><td style="vertical-align:top"><p>142/669</p></td><td style="vertical-align:top"><p>74/682</p></td><td style="vertical-align:top"><p>105/537</p></td><td style="vertical-align:top"><p>64/535</p></td><td style="vertical-align:top"><p>104/543</p></td><td style="vertical-align:top"><p>77/541</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>21.2</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>19.6</p></td><td style="vertical-align:top"><p>12.0</p></td><td style="vertical-align:top"><p>19.2</p></td><td style="vertical-align:top"><p>14.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference compared to placebo (%)</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001<sup> a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0006<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0298<sup> a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>MBS Free at 2&nbsp;hours</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n/N*</p></td><td style="vertical-align:top"><p>235/669</p></td><td style="vertical-align:top"><p>183/682</p></td><td style="vertical-align:top"><p>202/537</p></td><td style="vertical-align:top"><p>135/535</p></td><td style="vertical-align:top"><p>199/543</p></td><td style="vertical-align:top"><p>150/541</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>35.1</p></td><td style="vertical-align:top"><p>26.8</p></td><td style="vertical-align:top"><p>37.6</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>36.6</p></td><td style="vertical-align:top"><p>27.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference compared to placebo (%)</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0009<sup> a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001<sup> a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0016<sup> a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pain Relief at 2&nbsp;hours</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n/N*</p></td><td style="vertical-align:top"><p>397/669</p></td><td style="vertical-align:top"><p>295/682</p></td><td style="vertical-align:top"><p>312/537</p></td><td style="vertical-align:top"><p>229/535</p></td><td style="vertical-align:top"><p>304/543</p></td><td style="vertical-align:top"><p>247/541</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>59.3</p></td><td style="vertical-align:top"><p>43.3</p></td><td style="vertical-align:top"><p>58.1</p></td><td style="vertical-align:top"><p>42.8</p></td><td style="vertical-align:top"><p>56.0</p></td><td style="vertical-align:top"><p>45.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference compared to placebo</p></td><td style="vertical-align:top"><p>16.1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0006<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Sustained Pain Freedom 2 to 48&nbsp;hours</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n/N*</p></td><td style="vertical-align:top"><p>90/669</p></td><td style="vertical-align:top"><p>37/682</p></td><td style="vertical-align:top"><p>53/537</p></td><td style="vertical-align:top"><p>32/535</p></td><td style="vertical-align:top"><p>63/543</p></td><td style="vertical-align:top"><p>39/541</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>9.9</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>7.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference compared to placebo (%)</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0181<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0130<sup>b</sup></p></td></tr></tbody></table><p>*n=number of responders/N=number of patients in that treatment group</p><p><sup>a</sup> Significant p-value in hierarchical testing</p><p><sup>b</sup> Nominal p-value in hierarchical testing</p><p>MBS: most bothersome symptom</p><p>&nbsp;</p><p>Figure&nbsp;1 presents the percentage of patients achieving migraine pain freedom within 2&nbsp;hours following treatment in Study&nbsp;1.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1: Percentage of Patients Achieving Pain Freedom within 2&nbsp;Hours in Study&nbsp;1</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_7" o:spid="_x0000_i1028" type="#_x0000_t75"
 alt="Diagram&#10;&#10;Description automatically generated" style='width:453.5pt;
 height:320.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image001.png"
  o:title="Diagram&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="605" height="427" alt="Diagram

Description automatically generated" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p><p>Figure&nbsp;2 presents the percentage of patients achieving MBS freedom within 2&nbsp;hours in Study&nbsp;1.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2: Percentage of Patients Achieving MBS Freedom within 2&nbsp;Hours in Study&nbsp;1</strong></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_9" o:spid="_x0000_i1027"
 type="#_x0000_t75" alt="Line chart&#10;&#10;Description automatically generated"
 style='width:453.5pt;height:320.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image003.png"
  o:title="Line chart&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="605" height="427" alt="Line chart

Description automatically generated" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>The incidence of photophobia and phonophobia was reduced at 2&nbsp;hours following administration of NURTEC 75&nbsp;mg as compared to placebo in all 3 studies.</p><p>&nbsp;</p><p><u>Clinical efficacy: prophylaxis</u></p><p><u>&nbsp;</u></p><p>The efficacy of rimegepant was evaluated as a prophylactic treatment of migraine in a randomized, double-blind, placebo-controlled study (Study&nbsp;4).</p><p>&nbsp;</p><p>Study&nbsp;4 included male and female adults with at least a 1-year history of migraine (with or without aura). Patients had a history of 4 to 18 migraine attacks of moderate to severe pain intensity per 4-week period within the 12&nbsp;weeks prior to the screening visit. Patients experienced an average of 10.9&nbsp;headache days during the 28-day observational period, which included an average of 10.2 migraine days, prior to randomization into the study. The study randomized patients to receive rimegepant 75&nbsp;mg (N=373) or placebo (N=374) for up to 12&nbsp;weeks. Patients were instructed to take randomized treatment once every other day (EOD) for the 12-week treatment period. Patients were allowed to use other acute treatments for migraine (e.g., triptans, NSAIDs, paracetamol, antiemetics) as needed. Approximately 22% of patients were taking preventive medicinal products for migraine at baseline. Patients were allowed to continue in an open-label extension study for an additional 12&nbsp;months.</p><p>&nbsp;</p><p>The primary efficacy endpoint for Study&nbsp;4 was the change from baseline in the mean number of monthly migraine days (MMDs) during Weeks&nbsp;9 through 12 of the double-blind treatment phase. Secondary endpoints included the achievement of a &ge;&nbsp;50% reduction from baseline in monthly moderate or severe migraine days.</p><p>&nbsp;</p><p>Rimegepant 75&nbsp;mg dosed EOD demonstrated statistically significant improvements for key efficacy endpoints compared to placebo, as summarized in Table&nbsp;3 and shown graphically in Figure&nbsp;3.</p><p>&nbsp;</p><p><strong>Table&nbsp;3: Key Efficacy Endpoints for Study&nbsp;4</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rimegepant<br />75&nbsp;mg EOD</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br />EOD</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Monthly Migraine Days (MMD) Weeks&nbsp;9 through 12</strong></p></td><td style="vertical-align:top"><p><strong>N=348</strong></p></td><td style="vertical-align:top"><p><strong>N=347</strong></p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline</p></td><td style="vertical-align:top"><p>-4.3</p></td><td style="vertical-align:top"><p>-3.5</p></td></tr><tr><td style="vertical-align:top"><p>Change compared to placebo</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>0.010<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;&nbsp;50% Reduction in Moderate or Severe MMDs Weeks&nbsp;9 through 12</strong></p></td><td style="vertical-align:top"><p><strong>N=348</strong></p></td><td style="vertical-align:top"><p><strong>N=347</strong></p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>49.1</p></td><td style="vertical-align:top"><p>41.5</p></td></tr><tr><td style="vertical-align:top"><p>Difference compared to placebo</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>0.044<sup>a</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Significant p-value in hierarchical testing</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;3: Change from Baseline in Monthly Migraine Days in Study&nbsp;4</strong></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_4" o:spid="_x0000_i1026"
 type="#_x0000_t75" alt="A picture containing text, antenna, screenshot&#10;&#10;Description automatically generated"
 style='width:442pt;height:221.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image005.png"
  o:title="A picture containing text, antenna, screenshot&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="589" height="295" alt="A picture containing text, antenna, screenshot

Description automatically generated" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image006.png" /></p><p>&nbsp;</p><p><em>Long-term efficacy</em></p><p>Patients participating in Study&nbsp;4 were allowed to continue in an open-label extension study for an additional 12&nbsp;months. Efficacy was sustained for up to 1&nbsp;year in an open-label study extension in which patients received rimegepant 75&nbsp;mg every other day plus as needed on non-scheduled dosing days (Figure&nbsp;4). &nbsp;A portion composed of 203 patients<em> </em>assigned to rimegepant completed the overall 16-month treatment period. In these patients, the overall mean reduction from baseline in the number of MMDs averaged over the 16-month treatment period was 6.2 days.</p><p>&nbsp;</p><p><strong>Figure&nbsp;4: Longitudinal Plot of the Change in Mean Number of Monthly Migraine Days (MMDs) from the Observation Period Over Time during Double-Blind Treatment (Months&nbsp;1 to 3) and during Treatment with Open-label Rimegepant (Months&nbsp;4 to 16)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_10" o:spid="_x0000_i1025" type="#_x0000_t75" alt="Chart&#10;&#10;Description automatically generated"
 style='width:451.5pt;height:216.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image007.png"
  o:title="Chart&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="602" height="289" alt="Chart

Description automatically generated" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/18/msohtmlclip1/01/clip_image008.png" /></p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with NURTEC in all subsets of the pediatric population in the prophylactic treatment of migraine headaches (see section&nbsp;4.2 for information on pediatric use).</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with NURTEC in one or more subsets of the pediatric population in the acute treatment of migraine (see section&nbsp;4.2 for information on pediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following oral administration, rimegepant is absorbed with the maximum concentration at 1.5&nbsp;hours. Following a supratherapeutic dose of 300&nbsp;mg, the absolute oral bioavailability of rimegepant was approximately 64%.</p><p><u>&nbsp;</u></p><p><em>Effects of food</em></p><p>Following administration of rimegepant under fed conditions with a high-fat or low-fat meal, T<sub>max</sub> was delayed by 1&nbsp;to&nbsp;1.5&nbsp;hours. A high-fat meal reduced C<sub>max</sub> by 42 to 53% and AUC by 32 to 38%. A low-fat meal reduced C<sub>max</sub> by 36% and AUC by 28%. Rimegepant was administered without regard to food in clinical safety and efficacy studies.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The steady state volume of distribution of rimegepant is 120&nbsp;l. Plasma protein binding of rimegepant is approximately 96%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Rimegepant is the primary form (~77%) with no major metabolites (i.e., &gt;&nbsp;10%) detected in plasma.</p><p>&nbsp;</p><p>Based on <em>in vitro</em> studies, rimegepant is not an inhibitor of CYP1A2, 2B6, 2C9, 2C19, 2D6, or UGT1A1 at clinically relevant concentrations. However, rimegepant is a weak inhibitor of CYP3A4 with time-dependent inhibition. Rimegepant is not an inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The elimination half-life of rimegepant is approximately 11&nbsp;hours in healthy subjects. Following oral administration of [<sup>14</sup>C]-rimegepant to healthy male subjects, 78% of the total radioactivity was recovered in feces and 24% in urine. Unchanged rimegepant is the major single component in excreted feces (42%) and urine (51%).</p><p>&nbsp;</p><p><em>Transporters</em></p><p><em>In vitro</em>, rimegepant is a substrate of P‑gp and BCRP efflux transporters. Inhibitors of P‑gp and BCRP efflux transporters may increase plasma concentrations of rimegepant (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Rimegepant is not a substrate of OATP1B1 or OATP1B3. Considering its low renal clearance, rimegepant was not evaluated as a substrate of the OAT1, OAT3, OCT2, MATE1, or MATE2-K.</p><p>&nbsp;</p><p>Rimegepant is not an inhibitor of P‑gp, BCRP, OAT1, or MATE2-K at clinically relevant concentrations. It is a weak inhibitor of OATP1B1 and OAT3.</p><p>&nbsp;</p><p>Rimegepant is an inhibitor of OATP1B3, OCT2, and MATE1. Concomitant administration of rimegepant with metformin, a MATE1 transporter substrate, resulted in no clinically significant impact on either metformin pharmacokinetics or on glucose utilization. No clinical drug interactions are expected for rimegepant with OATP1B3 or OCT2, at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>Rimegepant exhibits greater than dose proportional increases in exposure following single oral administration, which appears to be related to a dose-dependant increase in bioavailability.</p><p>&nbsp;</p><p><u>Age, sex, weight, race, ethnicity</u></p><p>&nbsp;</p><p>No clinically significant differences in the pharmacokinetics of rimegepant were observed based on age, sex, race/ethnicity, body weight, migraine status, or CYP2C9 genotype.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>In a dedicated clinical study comparing the pharmacokinetics of rimegepant in subjects with mild (estimated creatinine clearance [CLcr] 60-89&nbsp;ml/min), moderate (CLcr 30-59&nbsp;ml/min), and severe (CLcr 15-29&nbsp;ml/min) renal impairment to that with normal subjects (healthy pooled control), a less than 50% increase in total rimegepant exposure was observed following a single 75&nbsp;mg dose. The unbound AUC of rimegepant was 2.57-fold higher in subjects with severe renal impairment. NURTEC has not been studied in patients with end-stage renal disease (CLcr &lt;&nbsp;15&nbsp;ml/min).</p><p><u>&nbsp;</u></p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>In a dedicated clinical study comparing the pharmacokinetics of rimegepant in subjects with mild, moderate, and severe hepatic impairment to that with normal subjects (healthy matched control), the exposure of rimegepant (unbound AUC) following a single 75&nbsp;mg dose was 3.89-fold higher in subjects with severe impairment (Child-Pugh class C). There were no clinically meaningful differences in the exposure of rimegepant in subjects with mild (Child-Pugh class A) and moderate hepatic impairment (Child-Pugh class B) compared to subjects with normal hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for rimegepant in humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, phototoxicity, reproduction or development, or carcinogenic potential.</p><p>&nbsp;</p><p>Rimegepant-related effects at higher doses in repeat-dose studies included hepatic lipidosis in mice and rats, intravascular hemolysis in rats and monkeys, and emesis in monkeys. These findings were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use (&ge;&nbsp;12 times [mice] and &ge;&nbsp;49 times [rats] for hepatic lipidosis, &ge;&nbsp;95 times [rats] and &ge;&nbsp;9 times [monkeys] for intravascular hemolysis, and &ge;&nbsp;37 times for emesis [monkeys]).</p><p>&nbsp;</p><p>In a fertility study in rats, rimegepant-related effects were noted only at the high dose of 150&nbsp;mg/kg/day (decreased fertility and increased pre-implantation loss) that produced maternal toxicity and systemic exposures &ge;&nbsp;95 times the maximum human exposure. Oral administration of rimegepant during organogenesis resulted in foetal effects in rats but not rabbits. In rats, decreased foetal body weight and increased incidence of foetal variations were observed only at the highest dose of 300&nbsp;mg/kg/day that produced maternal toxicity at exposures approximately 200 times the maximum human exposure. Additionally, rimegepant had no effects on pre- and postnatal development in rats at doses up to 60&nbsp;mg/kg/day (&ge;&nbsp;24 times the maximum human exposure) or on growth, development, or reproductive performance of juvenile rats at doses up to 45&nbsp;mg/kg/day (&ge;&nbsp;14 times the maximum human exposure).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>gelatin</p><p>mannitol (E421)</p><p>mint flavour</p><p>sucralose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unit dose blisters made of polyvinyl chloride (PVC), oriented polyamide (OPA) and aluminium foil and sealed with a peelable aluminum foil.</p><p>&nbsp;</p><p>Pack size</p><p>Unit dose 8&nbsp;x&nbsp;1 orally disintegrating tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer Europe MA EEIG
Belgium

Manufacturer 
Catalent UK Swindon Zydis Ltd
Frankland Road, Blagrove
Swindon, Wiltshire SN5 8RU
United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>